

## Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **July 1, 2024**, updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at [ab.bluecross.ca/dbl/publications.php](http://ab.bluecross.ca/dbl/publications.php).

Please refer to the **July 1, 2024**, updates for complete listings of products available by special authorization, restricted benefits, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at [ab.bluecross.ca/dbl/idbl\\_main1.php](http://ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

## Product supply shortages addressed for ADBL

Alberta Blue Cross® has confirmed that the shortage of Teva-Diltiazem XC 240 mg Extended-Release Tablet (DIN 02429330) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 8, 2024**. The following grouping was removed from the Critical Supply Product List **June 6, 2024**.

### DILTIAZEM HCL

#### 240 MG EXTENDED-RELEASE TABLET

00002429330	TEVA-DILTIAZEM XC	TEV	\$ 1.2212
00002256754	TIAZAC XC	VCL	\$ 1.7167

Alberta Blue Cross has confirmed that the shortage of Auro-Hydrocortisone 20 mg Tablet (DIN 02524473) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 11, 2024**. The following grouping was removed from the Critical Supply Product List **June 11, 2024**.

### HYDROCORTISONE

#### 20 MG TABLET

00002524473	AURO-HYDROCORTISONE	AUR	\$ 0.2958
00000030929	CORTEF	PFI	\$ 0.4078

continued next page

# PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortage of Jamp Candesartan-HCT 32 mg/25 mg Tablet (DIN 02473267) and Sandoz Candesartan Plus 32 mg/25 mg Tablet (DIN 02420740) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 12, 2024**. The following grouping was removed from the Critical Supply Product List **June 12, 2024**.

## CANDESARTAN CILEXETIL/ HYDROCHLOROTHIAZIDE

### 32 MG / 25 MG TABLET

00002421054	AURO-CANDESARTAN HCT	AUR	\$ 0.3008
00002473267	JAMP CANDESARTAN-HCT	JPC	\$ 0.3008
00002531267	NRA-CANDESARTAN HCTZ	NRA	\$ 0.3008
00002420740	SANDOZ CANDESARTAN PLUS	SDZ	\$ 0.3008
00002332957	ATACAND PLUS	AZC	\$ 1.4252

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

